Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

Riccardo Alessandro, Patrizia Diana, Girolamo Cirrincione, Stefania Raimondo, Simona Fontana, Francesca Monteleone, Marta Cristaldi, Daniele Bellavia, Mauro Manno, Stefano Forte, Samuele Raccosta, Giovanna Calabrese, Lorenzo Memeo, Gianluca Giavaresi, Daniele Bellavia, Mauro Manno, Samuele Raccosta

Risultato della ricerca: Article

53 Citazioni (Scopus)

Abstract

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.
Lingua originaleEnglish
pagine (da-a)1333-1345
Numero di pagine13
RivistaTheranostics
Volume7
Stato di pubblicazionePublished - 2017

Fingerprint

Interleukin-3 Receptors
Exosomes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth
Interleukin-3
Myeloid Cells
Drug Delivery Systems
Drug Resistance
Small Interfering RNA
Neoplasms
In Vitro Techniques
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cita questo

Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth. / Alessandro, Riccardo; Diana, Patrizia; Cirrincione, Girolamo; Raimondo, Stefania; Fontana, Simona; Monteleone, Francesca; Cristaldi, Marta; Bellavia, Daniele; Manno, Mauro; Forte, Stefano; Raccosta, Samuele; Calabrese, Giovanna; Memeo, Lorenzo; Giavaresi, Gianluca; Bellavia, Daniele; Manno, Mauro; Raccosta, Samuele.

In: Theranostics, Vol. 7, 2017, pag. 1333-1345.

Risultato della ricerca: Article

Alessandro, R, Diana, P, Cirrincione, G, Raimondo, S, Fontana, S, Monteleone, F, Cristaldi, M, Bellavia, D, Manno, M, Forte, S, Raccosta, S, Calabrese, G, Memeo, L, Giavaresi, G, Bellavia, D, Manno, M & Raccosta, S 2017, 'Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth', Theranostics, vol. 7, pagg. 1333-1345.
Alessandro, Riccardo ; Diana, Patrizia ; Cirrincione, Girolamo ; Raimondo, Stefania ; Fontana, Simona ; Monteleone, Francesca ; Cristaldi, Marta ; Bellavia, Daniele ; Manno, Mauro ; Forte, Stefano ; Raccosta, Samuele ; Calabrese, Giovanna ; Memeo, Lorenzo ; Giavaresi, Gianluca ; Bellavia, Daniele ; Manno, Mauro ; Raccosta, Samuele. / Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth. In: Theranostics. 2017 ; Vol. 7. pagg. 1333-1345.
@article{4f1467064c68429b86d1c0df86ccf0b4,
title = "Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth",
abstract = "Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.",
keywords = "Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia, BCR-ABL Positive; Mice; Receptors, Chronic, Chronic myeloid leukemia; Drug delivery; Drug resistance; Engineered exosomes; Interleukin 3; Animals; Antineoplastic Agents; Cell Line, Interleukin-3; Treatment Outcome; Medicine (miscellaneous); Pharmacology, Myelogenous, Toxicology and Pharmaceutics (miscellaneous), Tumor; Cell Proliferation; Disease Models",
author = "Riccardo Alessandro and Patrizia Diana and Girolamo Cirrincione and Stefania Raimondo and Simona Fontana and Francesca Monteleone and Marta Cristaldi and Daniele Bellavia and Mauro Manno and Stefano Forte and Samuele Raccosta and Giovanna Calabrese and Lorenzo Memeo and Gianluca Giavaresi and Daniele Bellavia and Mauro Manno and Samuele Raccosta",
year = "2017",
language = "English",
volume = "7",
pages = "1333--1345",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",

}

TY - JOUR

T1 - Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

AU - Alessandro, Riccardo

AU - Diana, Patrizia

AU - Cirrincione, Girolamo

AU - Raimondo, Stefania

AU - Fontana, Simona

AU - Monteleone, Francesca

AU - Cristaldi, Marta

AU - Bellavia, Daniele

AU - Manno, Mauro

AU - Forte, Stefano

AU - Raccosta, Samuele

AU - Calabrese, Giovanna

AU - Memeo, Lorenzo

AU - Giavaresi, Gianluca

AU - Bellavia, Daniele

AU - Manno, Mauro

AU - Raccosta, Samuele

PY - 2017

Y1 - 2017

N2 - Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.

AB - Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.

KW - Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia

KW - BCR-ABL Positive; Mice; Receptors

KW - Chronic

KW - Chronic myeloid leukemia; Drug delivery; Drug resistance; Engineered exosomes; Interleukin 3; Animals; Antineoplastic Agents; Cell Line

KW - Interleukin-3; Treatment Outcome; Medicine (miscellaneous); Pharmacology

KW - Myelogenous

KW - Toxicology and Pharmaceutics (miscellaneous)

KW - Tumor; Cell Proliferation; Disease Models

UR - http://hdl.handle.net/10447/225983

UR - http://www.thno.org/v07p1333.pdf

M3 - Article

VL - 7

SP - 1333

EP - 1345

JO - Theranostics

JF - Theranostics

SN - 1838-7640

ER -